Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Robertson

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorderSvetlana Hakobyan, Sebastian Luppe, David Rs Evans, et al.
Brain Communications|May 7, 2021
Tract-specific MRI measures explain learning and recall differences in multiple sclerosisMia Winter, Emma C Tallantyre, Thomas A W Brice, et al.
International Journal of MS Care|November 3, 2016
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' ExperiencesFreya Davies, Fiona Wood, Katherine E Brain, et al.
International Ophthalmology|October 13, 2016
Alemtuzumab-induced remission of multiple sclerosis-associated uveitisMark D Willis, Trevor P Pickersgill, Neil P Robertson, et al.
Multiple Sclerosis and Related Disorders|May 1, 2020
Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohortEmma C Tallantyre, Daniel Castle, Paul Karamura, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2019
Cerebrospinal fluid complement system biomarkers in demyelinating diseaseWioleta Milena Zelek, Dina Fathalla, Angharad Morgan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2018
Sarcoidosis following alemtuzumab treatment for multiple sclerosisMark D Willis, Ben Hope-Gill, Patrick Flood-Page, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosisRebecca Beesley, Valerie Anderson, Katharine E Harding, et al.
Neurology|December 18, 2012
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosisMark D Cossburn, Katharine Harding, Gillian Ingram, et al.
Brain Communications|November 11, 2021
CSF-resident CD4<sup>+</sup> T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosisJames Hrastelj, Robert Andrews, Samantha Loveless, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorderSvetlana Hakobyan, Sebastian Luppe, David Rs Evans, et al.
Brain Communications|May 7, 2021
Tract-specific MRI measures explain learning and recall differences in multiple sclerosisMia Winter, Emma C Tallantyre, Thomas A W Brice, et al.
International Journal of MS Care|November 3, 2016
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' ExperiencesFreya Davies, Fiona Wood, Katherine E Brain, et al.
International Ophthalmology|October 13, 2016
Alemtuzumab-induced remission of multiple sclerosis-associated uveitisMark D Willis, Trevor P Pickersgill, Neil P Robertson, et al.
Multiple Sclerosis and Related Disorders|May 1, 2020
Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohortEmma C Tallantyre, Daniel Castle, Paul Karamura, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2019
Cerebrospinal fluid complement system biomarkers in demyelinating diseaseWioleta Milena Zelek, Dina Fathalla, Angharad Morgan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2018
Sarcoidosis following alemtuzumab treatment for multiple sclerosisMark D Willis, Ben Hope-Gill, Patrick Flood-Page, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosisRebecca Beesley, Valerie Anderson, Katharine E Harding, et al.
Neurology|December 18, 2012
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosisMark D Cossburn, Katharine Harding, Gillian Ingram, et al.
Brain Communications|November 11, 2021
CSF-resident CD4<sup>+</sup> T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosisJames Hrastelj, Robert Andrews, Samantha Loveless, et al.
Pageof 13